TempoLife › Features › Prostate: enlargement, PSA and the screening argument

Prostate: enlargement, PSA and the screening argument

Prostate: enlargement, PSA and the screening argument: this guide covers benign enlargement and the symptoms that actually bother people (getting up at…

This guide is general education, not a diagnosis or an individual treatment plan. Urgent, severe or worsening symptoms belong with the local emergency service or a qualified clinician.

What this guide covers

This guide covers benign enlargement and the symptoms that actually bother people (getting up at night, weak stream, urgency, the feeling of not emptying), the IPSS symptom score with instant interpretation, what fluid timing and bladder training do before any medicine, alpha blockers and 5-alpha reductase inhibitors including the side effects men are not warned about, prostatitis and chronic pelvic pain in younger men, what a PSA number means at each age and what raises it that is not cancer (cycling, sex, infection), the screening debate presented as benefits and harms rather than a slogan, what an MRI-first pathway involves now, and saw palmetto's evidence.

One focused section asks: "PSA 4.2 at 62: what happens next".

How to use it

Start with the description that most closely matches your question about Prostate: enlargement, PSA and the screening argument. Use the evidence section to understand what is known, then use the boundary section to decide when self-education should stop and clinical care should begin.

The page keeps the main question, its evidence base and its limits together in one canonical place. That makes it useful as a quick orientation and avoids splitting a broad subject into shallow pages before each narrower answer has enough verified material of its own.

Search vocabulary in four languages

Terminology changes across borders. These are example phrases people use for the same subject in Estonian, Finnish, Russian and English; they are included as a practical vocabulary aid, not as hidden keywords.

Evidence and provenance

The evidence map below records the primary, official or openly licensed material chosen for this guide. It is deliberately visible so a reader can tell the difference between a rule published by an authority, a measured dataset and an editorial explanation.

Source: EAU guidelines on non-neurogenic male LUTS and on prostate cancer (uroweb.org, published and free), IPSS (public), ERSPC screening trial and Cochrane review (cited), EU Council Recommendation on cancer screening 2022 (EUR-Lex, reusable). · checked 2026-09-09

Source names are preserved even where an authority changes its web address. No figure is added to this launch page unless it is already present in the cited source description or can be computed from a named dataset.

Scope and boundaries

/men is a broad men's-health hub with one PSA line and /screening lists what is offered at what age; this is the organ, the symptom score and the decision itself.

Connected TempoLife guides

The following paths are the intentional hand-offs named in the brief. They keep adjacent subjects separate while making the next useful reference easy to find.

Why it belongs on TempoLife

/men, /bladder, /screening, /labs.

Frequently asked questions